{"entity":{"id":"nct05631262","kind":"trial","name":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 2 trial of Docetaxel in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","summary":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors is a phase 2 interventional study registered as NCT05631262 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 321 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: SKB264 and Docetaxel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05631262","url":"https://clinicaltrials.gov/study/NCT05631262"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel"],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05631262","phase":"2","setting":"A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":321,"outcomes":[]},"route":"/trials/nct05631262/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}